Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Sayin

Showing results (61-70 of 65) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 65 results.
Nature Communications|July 3, 2015
Farnesoid X receptor inhibits glucagon-like peptide-1 production by enteroendocrine L cellsMohamed-Sami Trabelsi, Mehdi Daoudi, Janne Prawitt, et al.
Science Advances|March 27, 2024
Glutamine antagonist DRP-104 suppresses tumor growth and enhances response to checkpoint blockade in <i>KEAP1</i> mutant lung cancerRay Pillai, Sarah E LeBoeuf, Yuan Hao, et al.
Biorxiv : the Preprint Server for Biology|July 10, 2023
Glutamine antagonist DRP-104 suppresses tumor growth and enhances response to checkpoint blockade in <i>KEAP1</i> mutant lung cancerRay Pillai, Sarah E LeBoeuf, Yuan Hao, et al.
Nature Medicine|October 3, 2017
Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysisRodrigo Romero, Volkan I Sayin, Shawn M Davidson, et al.
Nature|February 18, 2026
The integrated stress response promotes immune evasion through lipocalin 2Jozef P Bossowski, Ray Pillai, John Kilian, et al.
Pageof 7

Showing results (61-70 of 65) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 65 results.
Nature Communications|July 3, 2015
Farnesoid X receptor inhibits glucagon-like peptide-1 production by enteroendocrine L cellsMohamed-Sami Trabelsi, Mehdi Daoudi, Janne Prawitt, et al.
Science Advances|March 27, 2024
Glutamine antagonist DRP-104 suppresses tumor growth and enhances response to checkpoint blockade in <i>KEAP1</i> mutant lung cancerRay Pillai, Sarah E LeBoeuf, Yuan Hao, et al.
Biorxiv : the Preprint Server for Biology|July 10, 2023
Glutamine antagonist DRP-104 suppresses tumor growth and enhances response to checkpoint blockade in <i>KEAP1</i> mutant lung cancerRay Pillai, Sarah E LeBoeuf, Yuan Hao, et al.
Nature Medicine|October 3, 2017
Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysisRodrigo Romero, Volkan I Sayin, Shawn M Davidson, et al.
Nature|February 18, 2026
The integrated stress response promotes immune evasion through lipocalin 2Jozef P Bossowski, Ray Pillai, John Kilian, et al.
Pageof 7